Cargando…

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer

Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qiang, Chen, Dong-Sheng, Liu, Yuan-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/
https://www.ncbi.nlm.nih.gov/pubmed/35359396
http://dx.doi.org/10.3389/fonc.2022.853211
_version_ 1784677365418295296
author Wei, Qiang
Chen, Dong-Sheng
Liu, Yuan-Hua
author_facet Wei, Qiang
Chen, Dong-Sheng
Liu, Yuan-Hua
author_sort Wei, Qiang
collection PubMed
description Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.
format Online
Article
Text
id pubmed-8960313
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89603132022-03-30 Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer Wei, Qiang Chen, Dong-Sheng Liu, Yuan-Hua Front Oncol Oncology Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect. Frontiers Media S.A. 2022-03-10 /pmc/articles/PMC8960313/ /pubmed/35359396 http://dx.doi.org/10.3389/fonc.2022.853211 Text en Copyright © 2022 Wei, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wei, Qiang
Chen, Dong-Sheng
Liu, Yuan-Hua
Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title_full Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title_fullStr Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title_full_unstemmed Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title_short Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
title_sort case report: niraparib-related pulmonary embolism during the treatment of brca mutant advanced ovarian cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960313/
https://www.ncbi.nlm.nih.gov/pubmed/35359396
http://dx.doi.org/10.3389/fonc.2022.853211
work_keys_str_mv AT weiqiang casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer
AT chendongsheng casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer
AT liuyuanhua casereportniraparibrelatedpulmonaryembolismduringthetreatmentofbrcamutantadvancedovariancancer